Abstract:

Objective   To observe the clinical effects of sipulin combined with radiotherapy and chemotherapy. Methods  147 patients were randomly divided into 2 groups: the sipulin group was treated with sipulin combined with radiotherapy and chemotherapy(n=75) and the control group was only treated with radiotherapy and chemotherapy(n=72).　The methods of radiotherapy and chemotherapy were identical in the two groups. The sipulin group received intravenous infusions of sipulin(10mL in 250mL 0.9% NS) for 14 days, 4-6 cycles (21days in one cycle). The clinical indexes were observed and analyzed. Results   The efficiency rate was 60.0% in the sipulin group and 48.6% in the control group, and there was no significant difference between the two groups(P＞0.05). The 1-and 2-year survival rates in the sipulin group （58.9% and 41.1%）were significantly higher than those in the control group (42.3% and 25.4%) (P＜0.05). The quality of life  and the counts of T and NK cells after treatment in the sipulin group were significantly increased. The decline of the hematocyte count, the side effect of the alimentary tract and radioesophagitis were  evidently reduced in the sipulin group compared with the control group. Conclusion  Sipulin injection is effective and safe as an adjuvant in radiotherapy and chemotherapy for lung cancer in medium and terminal stages.

Key words: Lung cancer in medium and terminal stages; Chemotherapy; Radiotherapy; Sipulin injection